Company Focus
BioNTech
Latest BioNTech News
Biotechnology
German biotech BioNTech today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress. The firm’s shares were down 3.4% at $89.11 in pre-market trading following the results. 4 August 2026
Related News
Latest News & Features of interest to BioNTech
Biotechnology
Vedanta Biosciences, a Cambridge, Massachusetts-based late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal disease, has secured $60 million in funding and named two new board appointments ahead of pivotal Phase III data for its lead candidate. 7 August 2026
Pharmaceutical
India dispatched 13 tonnes of BCG vaccines to Afghanistan last month to bolster its child immunization drive. The move underscores India’s role as a regional health partner, extending support to a country grappling with fragile healthcare infrastructure. 7 August 2026
Biotechnology
Cambridge, USA-based clinical-stage biotech Marengo Therapeutics has announced two important milestones reflecting the advancement of its TriSTAR platform: the appointment of Saso Cemerski as senior vice president, head of immunology; and nomination of the first development candidate under its TriSTAR strategic collaboration with Ipsen.
. 6 August 2026
Biotechnology
The US Food and Drug Administration (FDA) has accepted Merck & Co's supplemental Biologics License Application (sBLA) for its respiratory syncytial virus (RSV) antibody Enflonsia (clesrovimab-cfor), seeking to expand its indication to children under two years old at increased risk of severe RSV disease through their second RSV season. 6 August 2026
Biotechnology
Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved mFlusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. 6 August 2026
Biotechnology
US clinical-stage biotechnology company Expedition Therapeutics, which is developing novel oral small molecule therapies for inflammatory and respiratory diseases, today announced the closing of an oversubscribed $115 million Series B financing. 5 August 2026
Biotechnology
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity (romosozumab) and several newer medicines outweighed declining sales of products facing pricing or biosimilar pressure. 5 August 2026
Biotechnology
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology. 5 August 2026
Biotechnology
South Korean immune-oncology company Vaxcellbio revealed it has signed a strategic memorandum of understanding (MOU) with Canadian biotechnology company Myellama to jointly develop a novel multiple myeloma therapy based on the National Research Council Canada's (NRC) next-generation NK cell engager technology. 4 August 2026
Biotechnology
German biotech BioNTech today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress. The firm’s shares were down 3.4% at $89.11 in pre-market trading following the results. 4 August 2026
Latest In Brief for BioNTech
Pharmaceutical
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. 25 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze